Trial Profile
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms KBCSG-TR1315
- 22 Mar 2019 Status changed from not yet recruiting to completed.
- 24 Feb 2014 New trial record